| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
,
SYLVIA L. ASA,
KALMAN KOVACS,
PAUL MULLER and
HARLEY S. SMYTH
Departments of Pathology (S.Y., S.L.A., K.K.) and Neurosurgery (P.M.), St. Michaels Hospital, and the Department of Neurosurgery, Wellesley Hospital (H.S.S.), University of Toronto Toronto,Ontario, M5B 1W8 Canada
Address all correspondence and requests for reprints to: S. L. Asa, M.D., Department of Pathology, St. Michaels Hospital, 30 Bond Street, Toronto, Ontario, M5B 1W8 Canada.
The reverse hemolytic plaque assay was used to study hormone release in vitro by seven clinically nonfunctioning human pituitary adenomas associated with no clinical or biochemical evidence of hormone excess. Four of seven tumors were oncocytomas, one a null cell adenoma, and two gonadotroph adenomas based on immunocytochemical and ultrastructural features. In all seven tumors, plaques were formed with antiserum against βFSH; four produced plaques for βLH, and five for glycoprotein hormone
-subunit. The percentageof plaqueforming cells and the mean size of plaques were smaller thanthose of clinically functioning adenomas studied for comparison (five GH- and/or PRL-producing adenomas).These results correlated with those of hormone release in tissue culture, immunocytochemistry on paraffin secretions of the tumors, and immunocytochemistry after reverse hemolytic plaque assay. We conclude that clinically nonfunctioning pituitary adenomas release small quantities of hormones, primarily gonadotropins, and that hormone release is attributable to only a small percentage of tumor cells.
* This work was supported in part by the Connaught Foundation, the Deans Fund of the University of Toronto, Faculty of Medicine,the St. Michaels Hospital Research Society, and Grants MA-10215 and MT-6349 awarded by the Medical Research Council of Canada.
Supported by the Toranomon Hospital and the Okinaka Memorial Institute of Medical Research, Tokyo, Japan.
Received April 22, 1988.
This article has been cited by other articles:
![]() |
C.-O. Evans, P. Reddy, D. J. Brat, E. B. O'Neill, B. Craige, V. L. Stevens, and N. M. Oyesiku Differential Expression of Folate Receptor in Pituitary Adenomas Cancer Res., July 15, 2003; 63(14): 4218 - 4224. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Nakamura, T. Usui, H. Mizuta, H. Murabe, S. Muro, M. Suda, K. Tanaka, I. Tanaka, A. Shimatsu, and K. Nakao Characterization of Prophet of Pit-1 Gene Expression in Normal Pituitary and Pituitary Adenomas in Humans J. Clin. Endocrinol. Metab., April 1, 1999; 84(4): 1414 - 1419. [Abstract] [Full Text] |
||||
![]() |
T. R. Kumar, K. E. Graham, S. L. Asa, and M. J. Low Simian Virus 40 T Antigen-Induced Gonadotroph Adenomas: A Model of Human Null Cell Adenomas Endocrinology, July 1, 1998; 139(7): 3342 - 3351. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ferone, S. Lastoria, A. Colao, P. Varrella, G. Cerbone, W. Acampa, B. Merola, M. Salvatore, and G. Lombardi Correlation of Scintigraphic Results Using 123I-Methoxybenzamide with Hormone Levels and Tumor Size Response to Quinagolide in Patients with Pituitary Adenomas J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 248 - 252. [Abstract] [Full Text] |
||||
![]() |
P. Chanson, J. Pantel, J. Young, B. Couzinet, J.-M. Bidart, and G. Schaison Free Luteinizing-Hormone Beta-Subunit in Normal Subjects and Patients with Pituitary Adenomas J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1397 - 1402. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |